预防性扩大野同步放化疗治疗盆腔淋巴结阳性宫颈癌的多中心观察研究
本研究在东亚和东南亚11个国家开展多中心观察,纳入106例未治疗宫颈鳞癌患者,评估每周顺铂同步预防性扩大野放化疗的临床结局。可评估95例,中位随访56个月,2年局部控制率96%、无进展生存率78%、总生存率90%,提示该方案可行有效。
要点
- 95例可评估患者中76例(80%)完成4或5周期每周顺铂化疗。
- 急性3级白细胞减少发生率为21%,晚期3级胃肠道毒性为3%。
- 2年局部控制率96%、无进展生存率78%、总生存率90%。
核心结论
- 预防性扩大野同步放化疗联合每周顺铂对东亚和东南亚局部晚期宫颈癌患者可行且有效。
研究设计与样本
- 多中心观察研究,2007年10月至2016年5月在东亚和东南亚11个国家纳入106例未治疗宫颈鳞癌患者。
- 放疗包括盆腔照射(总剂量50 Gy分25次,含中心遮挡)、预防性主动脉旁区域照射(36-40 Gy分20次)及腔内近距离放疗。
- 每周顺铂40 mg/m2共5周期,可评估95例,中位随访56个月。
主要发现
- 95例可评估患者中76例(80%)接受4或5周期化疗。
- 急性3级白细胞减少20例(21%),晚期3级胃肠道毒性3%。
- 全部患者2年局部控制率96%、无进展生存率78%、总生存率90%。
临床怎么用
- 对局部晚期盆腔淋巴结阳性宫颈癌,可考虑预防性扩大野同步放化疗联合每周顺铂。
局限性
- 9例存在重大方案违背、2例因一般状况恶化未治疗,最终仅95例可评估。
- 为观察性研究,未设对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This multi-institutional observational study conducted among 11 countries in East and Southeast Asia aimed to assess the clinical outcomes of prophylactic extended-field concurrent chemoradiation therapy using weekly cisplatin for patients with locally advanced cervical cancer. METHODS AND MATERIALS: Between October 2007 and May 2016, 106 patients with untreated squamous cell carcinoma of the cervix were enrolled in the present study. Radiation therapy consisted of pelvic irradiation (total dose, 50 Gy in 25 fractions including central shielding), prophylactic paraortic regional irradiation (36-40 Gy in 20 fractions), and either high- or low-dose-rate intracavitary brachytherapy (ICBT) according to institutional practice. The planned point A dose was 21 to 28 Gy in 3 to 4 fractions for high-dose-rate ICBT and 40 to 41 Gy in 1 to 2 fractions for low-dose-rate ICBT. Five cycles of weekly cisplatin (40 mg/m2) were administered during the radiation therapy course. RESULTS: A total of 106 patients were enrolled. Of these, 9 had major protocol violations and 2 did not receive treatment because of worsened general condition. Thus, 95 patients were evaluable. The median follow-up was 56 months. Of the 95 patients, 76 (80%) received 4 or 5 cycles of chemotherapy. Acute grade 3 leukopenia was observed in 20 of the patients (21%), and late grade 3 gastrointestinal toxicity was observed in 3%. The 2-year local control, progression-free survival, and overall survival rate for all patients were 96%, 78%, and 90%, respectively. CONCLUSIONS: The results indicated that prophylactic extended-field concurrent chemoradiation therapy using weekly cisplatin is feasible and effective for patients with locally advanced cervical cancer in East and Southeast Asia.
引用
- Wakatsuki M, Kato S, Ohno T, et al. Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia. Int J Radiat Oncol Biol Phys. 2019. PMID: 31125594. doi:10.1016/j.ijrobp.2019.04.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。